SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

DelMar Pharmaceuticals Presents Interim Data On VAL-083 Demonstrating Favorable Outcomes In Both Newly- Diagnosed And Recurrent GBM At AACR Annual Meeting II

SAN DIEGO, June 22, 2020 /PRNewswire/ --DelMar Pharmaceuticals, Inc.(NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor

Benzinga · -

SAN DIEGO, June 22, 2020 /PRNewswire/ --DelMar Pharmaceuticals, Inc.(NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced positive interim data from its two Phase 2 trials of VAL-083 for the treatment of glioblastoma multiforme (GBM) demonstrating improved outcomes over current standard of care as both a first-line treatment and for recurrent GBM. The data, presented in two posters at the 2020 American Association for Cancer Research Virtual Annual Meeting II, support the Company's planned participation in the Global Coalition for Adaptive Research's (GCAR) Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) clinical trial. DelMar previously announced its invitation from GCAR to participate in the selective GBM AGILE study. This pivotal study, with its robust trial design, industry leading partners, and strong regulatory endorsement, is intended to serve as the basis for VAL-083's new drug application (NDA) submission and registration.